Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Cash & Current Investments (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Cash & Current Investments for 8 consecutive years, with $162.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Current Investments rose 159.66% to $162.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $162.6 million, a 159.66% increase, with the full-year FY2024 number at $47.2 million, down 56.6% from a year prior.
  • Cash & Current Investments was $162.6 million for Q3 2025 at Whitehawk Therapeutics, down from $177.2 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $231.1 million in Q1 2025 to a low of $36.8 million in Q2 2021.
  • A 5-year average of $123.8 million and a median of $129.8 million in 2022 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: skyrocketed 241.36% in 2021, then plummeted 56.6% in 2024.
  • Whitehawk Therapeutics' Cash & Current Investments stood at $149.0 million in 2021, then rose by 15.82% to $172.6 million in 2022, then tumbled by 36.92% to $108.8 million in 2023, then tumbled by 56.6% to $47.2 million in 2024, then skyrocketed by 244.22% to $162.6 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Cash & Current Investments are $162.6 million (Q3 2025), $177.2 million (Q2 2025), and $231.1 million (Q1 2025).